

Curriculum Vitae

David V. Serreze, Ph.D.

The Jackson Laboratory
Bar Harbor, Maine 04609
(207) 288-6403
FAX (207) 288-6079

Education

University of Maine, Orono, Maine	B.S.	1979	Biology
University of Maine, Orono, Maine	M.S.	1982	Microbiology
University of Maine, Orono, Maine	Ph.D.	1990	Microbiology

Research Positions

3/05-present-Professor, The Jackson Laboratory, Bar Harbor, Maine

2/00-3/05- Associate Professor, The Jackson Laboratory, Bar Harbor, Maine

7/94-2/00-Assistant Professor, The Jackson Laboratory, Bar Harbor, Maine

5/98-12/17 - Adjunct Research Professor of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts

12/17-present - Adjunct Associate Professor of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts

6/93 -6/94 - Research Scientist, The Jackson Laboratory, Bar Harbor, Maine

6/91-6/93- American Diabetes Association Post-Doctoral Fellow, The Jackson Laboratory, Bar Harbor, Maine

5/85-6/91 - Sr. Research Asst., The Jackson Laboratory, Bar Harbor, Maine

8/84-2/85 - Manufacturing Reagents Technician, Ventrex Laboratories, Portland, Maine

12/82-4/84 - Research Technician, Dept. of Microbiology, Univ. of Maine

2/82-10/82 - Laboratory Technician, Dept. of Food Science, Univ. of Maine

1/80-12/1981 - Graduate Assistant, Dept. of Microbiology, Univ. of Maine

Research Interests

Genetic mechanisms for induction and maintenance of immunological tolerance.
Development of mouse gene models for understanding autoimmune diseases.
Genetics of susceptibility to insulin dependent diabetes in mice.

Academic Honors

B.S. in Biology with Distinction, Univ. of Maine, 1979

Alpha Zeta (life science honor society) Univ. of Maine Chapter, 1978

American Diabetes Association Travel Award-Top 5 Abstracts, International Research Symposium on Immunology of Diabetes, 1987.

American Diabetes Association Mentor Based Post-Doctoral Fellowship, 1991

Merck Scholar in Immunology, 1995-1996

Invited Lecture: Immunology of Diabetes Society Meeting, Orvieto, Italy, October 1995

Invited Plenary Session Lecture: 58th Annual Scientific Sessions of the American Diabetes Association, Chicago, Illinois, June 1998

Applebaum Visiting Distinguished Professor of Medicine, Univ. of Florida College of Medicine, 1998

Invited Lecture: Autoimmunity Session, American Association of Immunologists Meeting, Washington DC, April 1999

Invited Plenary Session Lecture: Annual Meeting of the Canadian Diabetes Association, Halifax, Nova Scotia, October 2000

Invited Lecture: Genetics Session, Immunology of Diabetes Society Meeting, Copper Mountain, Colorado, October 2002

Juvenile Diabetes Research Foundation, Mary Jane Kugal Research Award, 2003, 2006, 2009

Invited lecture: Immunology of Diabetes Society Meeting, Cambridge, U.K., March/April 2004.

Australasian Society of Immunology Invited International Speaker Tour, May 2004.

Invited Lecture: New England Immunology Conference, November 2004.

Invited Keynote Address: The BB rat turns 30, Ottawa, Ontario, Canada, December 2004

Invited Lecture: European Association for the Study of Diabetes/Juvenile Diabetes Research Foundation Joint Workshop, Oxford, England, August 2005.

Invited Overview lecture: Integrated European Union workshop on "The side of the victim: beta cell destruction in T1DM" and "The side of the aggressor: immunology of T1DM". Leiden, The Netherlands, March 2006.

Invited Keynote Address: National Institutes of Health Autoimmune Retinitis Workshop, Bethesda, Maryland, April, 2006.

Invited lecture: Merck sponsored conference "The Thyroid and Autoimmunity". Noordwijk, The Netherlands, June 2006

Invited lecture: New York Academy of Sciences Conference, Animal Models for Type 1 Diabetes and Multiple Sclerosis, San Francisco, CA, November 2006

Juvenile Diabetes Research Foundation, Gerold and Kayla Grodsky Award for outstanding contributions to diabetes research, May 2007

Invited lecture: 3rd Aegean Conference on "Autoimmunity: Mechanisms and Novel Treatments", Rhodes, Greece, October 2007

Invited lecture: Immunology of Diabetes Society meeting, Miami, Florida, November 2007

The Jackson Laboratory National Council Award for Scientific Achievement, August 2009

Invited lecture: 4th Aegean Conference on "Autoimmunity: Mechanisms and Novel Treatments", Crete, Greece, October 2009

Invited lecture: 70th Annual Scientific Sessions of the American Diabetes Association, Orlando, Florida, June 2010

Invited Lecture: New England Immunology Conference, November 2010

Invited speaker/round table discussant: *Nature Medicine* symposium on autoimmunity. Seon, Germany, June 2011

Invited lecture: 5th Aegean Conference on "Autoimmunity: Mechanisms and Novel Treatments", Crete, Greece, September 2011

Invited lecture: Keystone Symposium on Immunopathology of Type 1 Diabetes, Whistler, British Columbia, April 2013

Invited lecture: German Medical Council meeting on autoimmune diseases, Munster, Germany, November 2013

Invited lecture: 74th annual American Diabetes Association meeting, San Francisco, California, June 2014

Invited lecture: Immunology of Diabetes Society meeting, Munich, Germany, April 2015

Invited lecture: Symposium for the 60th Anniversary of Tongji Hospital Relocation from Shanghai to Wuhan China, October 2015

Invited lecture: Immunology of Diabetes Society meeting, San Francisco, California, January 2017

Faculty of 1000 Member (Immunology) 2002-present

Extramural Research Support

Current Support

Principal Investigator - NIH Grant DK095735. B-lymphocyte targeting therapies for autoimmune diabetes.

Funding period 4/13-3/27

OD030187 The Jackson Laboratory for precision genetics (project leader)
Funding period awarded 9/2020-8/25

JAX-DIF-DVS-20-ICI. Mapping genes uniquely contributing to immune check inhibitor (ICI) autoimmunity complications.

Funding period 3/20-5/21

Principal Investigator - Mark Foundation for Cancer Research Aspire Award 280052-0522 Identifying genes uniquely contributing to ICI induced immune

related adverse events (irAE),
Funding period 6/21-5/23

Past Support

Principal Investigator - *American Cancer Society Grant IRG-155G: Oncogenic role of *emv-30* in NOD-*scid* mice: development of an *emv-30* negative congenic stock.*

Funding period: 7/92 - 6/93

Principal Investigator - *Juvenile Diabetes Foundation Research Grant 195134. Testing human autoimmune diabetes susceptibility in mice.*

Funding period 9/95-8/97

Principal Investigator - *NIH Grant AI41469. Virus encoded mimitope processing in autoimmune diabetes.*

Funding period: 6/97 - 5/00

Principal Investigator - *Juvenile Diabetes Foundation Research Grant 1998-95. Role of MHC class I in autoimmune diabetes.*

Funding period 7/98-6/00

Principal Investigator - *Juvenile Diabetes Foundation Research Grant 1999-580. B lymphocyte antigen presentation in autoimmune diabetes.*

Funding period 8/97-7/01

Principal Investigator - *Juvenile Diabetes Foundation Research Grant 2001-535. Modeling human MHC class I diabetes functions in mice.*

Funding period 8/01-7/04

Principal Investigator - *Juvenile Diabetes Foundation Research Grant 2003-517. Role of B cells in T cell mediated autoimmune diabetes.*

Funding period 8/03-7/06

Principal Investigator - *Juvenile Diabetes Foundation Research Grant 2005-916. Agents for reversing diabetogenic dendritic cell defects.*

Funding period 8/05-7/08

Principal Investigator - *NIH Grant DK51090. Antigen presenting cell defects in autoimmune diabetes.*

Funding period: 6/96 - 5/10

Co-Principal Investigator - *Juvenile Diabetes Foundation Research Grant 192015. Defective macrophage differentiation and function in NOD/Lt mice.*

Funding period: 9/92 - 8/94

Co-Principal Investigator - *Juvenile Diabetes Foundation Research Grant 193822.*

Development of a gene therapy model for IDDM prevention in NOD mice.

Funding period: 9/94 - 8/96

Co-Principal Investigator - *NIH Grant DK27722.* Pathogenesis of autoimmune diabetes in mice.

Funding period: 4/94 - 6/05

Principal Investigator - *Juvenile Diabetes Foundation Research Grant 180536.*

Dendritic cell conditioning for type 1 diabetes prevention.

Funding period 9/07-8/10

Principal Investigator - (Project 3) *Juvenile Diabetes Foundation Research*

Program Project Grant 2005-1155. Identification of diabetogenic T cells in humanized mice.

Funding period 8/05-7/11

Principal Investigator - *Juvenile Diabetes Foundation Research Grant 2007-538.*

Optimizing B-lymphocyte targeted type-1 diabetes therapies.

Funding period 9/10-8/11

Project Leader – *NIH Beta Cell Biology Consortium TCPA award DK072473.*

Establishing immunological tolerance to transplanted pancreatic β cells.

Funding period 9/11-8/13

Principal Investigator - *Juvenile Diabetes Foundation Research Grant 17-2011-651.* Antigen specific tolerance in models of human T1D.

Funding period 9/11-8/13

Principal Investigator - *Juvenile Diabetes Foundation Research Grant 17-2011-659.*

Optimization of B-lymphocyte directed type-1 diabetes interventions.

Funding period 8/11-7/14

Principal Investigator – *American Diabetes Assoc. Research Grant 17-2011-659.*

Dendritic cell therapies for autoimmune diabetes.

Funding period 8/11-7/14

Principal Investigator - Harry and Leona Helmsley Foundation. A Microparticle Based Approach for Preserving Beta Cell Mass.

Funding period 4/14-3/15

*Principal Investigator - NIH Grant DK097610. Type 1 diabetes mouse resource.
Funding period 9/12-8/17*

*Principal Investigator - NIH Grant DK46266. Diabetogenic role of MHC class I alleles in NOD mice.
Funding period 6/93 - 6/20*

*Principal Investigator – JDRF Type 1 Diabetes Humanized Mouse Initiative.
Funding period 2/18-1/20*

*NIH grant U54 OD020351 The Jackson Laboratory Center for Precision Genetics: From New Models to Novel Therapeutics - DMU Project 2: New strains for modeling and for hosting human autoimmune diseases
Role: Project Leader
Funding period 8/15-6/20*

Diabetes Research Connection P20-0201 Identifying genes uniquely contributing to ICI induced versus spontaneous diabetes-awarded to Dr. Jeremy Racine 9/2

External Peer Review Duties

External Grant Review Panels

Standing member, National Institutes of Health

-Hypersensitivity, Allergy, and Immunological Diseases Study Section (2006-2010)

Ad hoc reviewer, National Institutes of Health:

-Hypersensitivity, Allergy, and Immunological Diseases Study Section (2006-2010)

-Immunological Sciences Study Section

-Transplantation, Tolerance, and Tumor Immunology Study Section

-Metabolism Study Section

-Mammalian Genetics Study Section

-Genes in Health and Disease Study Section

-Special Emphasis Study Section: Immunopathogenesis of Type I Diabetes Mellitus

-Special Emphasis Study Section: Biology of the pancreatic β cell

-Special Emphasis Study Section: Model systems towards development of human gene therapy

- Special Emphasis Study Section: New therapies for type I diabetes and its complications
- Special Emphasis Study Section: Diabetes centers of excellence
- Special Emphasis Study Section: Innovative grants on immune tolerance
- Special Emphasis Study Section: Gene transfer approaches to enhance islet transplantation
- Special Emphasis Study Section: Innovative partnerships in type 1 diabetes research
- Special Emphasis Study Section: Type 1 diabetes program project grants
- Special Emphasis Study Section: High-end instrumentation grant program: flow cytometry
- Special Emphasis Study Section: Bio samples from diabetes clinical studies
- Special Emphasis Study Section: Innovative approaches for type 1 diabetes interventions
- Special Emphasis Study Section: Cooperative study group for autoimmune disease prevention
- Special Emphasis Study Section: Research using subjects from the TrialNet Biobank (DP3)
- Special Emphasis Study Section: Early stage pharmacological validation of novel targets and accompanying pre-therapeutic leads for diseases of interest to NIDDK
- Special Emphasis Study Section: Small Business: Endocrinology, Metabolism, Nutrition, and Reproductive Sciences
- Ad Hoc Reviewer, National Institutes of Health, Special Emphasis Study Section: Model Systems Towards Development of Human Gene Therapy
- Special Emphasis Study Section: NIH Immunology Fellowships
- Special Emphasis Study Section: Immune mechanisms in autoimmunity and allergy
- Special Emphasis Study Section: NIDDK Central Repositories Sample access
- Ad Hoc Reviewer: NIDDK K award review study section
- Ad Hoc Reviewer: NIDDK F award review study section
- Ad Hoc Reviewer: NIDDK HIRN program study section
- Ad Hoc Reviewer: NIDDK Immune engineering for type 1 diabetes interventions study section
- Ad Hoc Reviewer: Genes in Health and Disease study section
- Diabetes UK
- Wellcome Trust, Type 1 Diabetes Advisory Committee
- NIDDK Catalyst Award Study Section
- NIDDK The autoantigens and neoantigensfunction in the etiology and pathophysiology of type 1 diabetes

Standing member, Juvenile Diabetes Foundation International, Medical Sciences Review Committee (2001-2009)

Juvenile Diabetes Foundation International, Innovative Grant Review Committee (2010-present)

Ad hoc grant reviewer, United States Veterans Administration

Ad hoc grant reviewer, Canadian Diabetes Association

Manuscript Reviews for Research Journals

Section Editor 2004-2008, *Journal of Immunology*

Associate Editor 2002-2004, *Journal of Immunology*

Editorial Board Member 2005-2007, *Clinical Immunology*

Editorial Board 2021-present, *Frontiers in Immunology*

Ad hoc reviewer: *Diabetes, Diabetologia, Journal of Immunology, Nature Medicine, Nature Genetics, Nature Reviews, Immunity, Proc. Natl. Acad. Sci. USA, Journal of Clinical Investigation, Journal of Experimental Medicine, Genomics, FASEB Journal, Laboratory Animal Science, Journal of Cancer, Mammalian Genome, Journal of Autoimmunity, Diabetes / Metabolism Reviews, Autoimmunity, International Immunology, Clinical Immunology, Trends in Immunology, American Journal of Human Genetics, PLoS One, PLoS Genetics, American Journal of Transplantation, Immunology, American Journal of Pathology, Genes and Immunity, Scientific Reports, Frontiers in Immunology, Nature Regenerative Medicine*

Post Doctoral Fellows/Students

-Jennifer Dwyer, PhD, post-doctoral fellow 2017-present

-Jeremy Racine, PhD, post-doctoral fellow 2014-2020

-Maximiliano Presa, PhD, post-doctoral fellow 2012-2017

-Caroline McPhee, DVM, PhD, post-doctoral fellow 2011-2014

-John Driver, PhD, post doctoral fellow 2005-2011

-Marijke Niens, PhD, post doctoral fellow 2008-2011

-Felix Scheuplein, PhD, post doctoral fellow 2006-2009

-Yi-Guang Chen, PhD, post doctoral fellow, 2002-2007

-Michele P Marron, PhD, post doctoral fellow, 2000-2004

-Caroline Choisy-Rossi, PhD post doctoral fellow, 2002-2004

-Pablo A Silveira, PhD, post doctoral fellow, 2000-2003

-Robert T Graser, PhD, post doctoral fellow, 1997-2000

-Qiming Wang, PhD graduate student, Tufts Medical School, 2014-present

- Todd Pearson, PhD graduate student, University Massachusetts Medical Center, 1999-2003
- Anna Quinlan, Atherton High School, Atherton CA, 2018 Jackson Laboratory Summer Student
- Isabel Stewart, University of Vermont, 2017 Jackson Laboratory Summer Student
- Jennifer Allocco, University of Connecticut, 2016 Jackson Laboratory Summer Student
- Rebecca O'Donnell, MDI High School, 2010 Jackson Laboratory Summer Student
- Shannon Bean, Rochester Institute of Technology, 2009 Jackson Laboratory Summer Student
- Alexandra Grier, Williams College, 2005, 2006 Jackson Laboratory Summer Student
- Ashley Bamman, Boston University, 2003 Jackson Laboratory Summer Student
- Joseph Dombrowski, Florida State University, 2002 Jackson Laboratory Summer Student
- Brian Stadinski, Bucknell University, 2001 Jackson Laboratory Summer Student
- Amanda Leinbaugh, Maine School of Science and Mathematics, 1999 academic year student
- Scott Richard, Albany College of Medicine, 1998 medical student summer intern
- Erin Nelli, State University of New York, Geneseo, 1998 Jackson Laboratory Summer Student
- Laurie Snow, Ellsworth High School, 1997 academic year student
- Sara Anne Fleming, Cornell University, 1996 Jackson Laboratory Summer Student
- Erik Cattelle, Ellsworth High School, 1996 academic year student
- Emmie Chen, Harvard University, 1995 Jackson Laboratory Summer Student
- Amy Patterson, Ellsworth High School, 1995 academic year student

Institutional Service

- Research Grants Committee 1995-present (Chairman since 1997)
- Research Animal Facilities Committee 2000-2017
- Genetics Resources Committee 2012-present
- Scientific Advisory Committee 1999, 2011-2014
- Post-Doctoral Training Committee 2010-2014
- Promotions Committee 2012-present
- Faculty Recruiting Committee 2006-2009
- Organizer, Immunology/Hematology Interest Group 1995-2007
- Seminars Committee 1997-2001
- Education Committee, 2000

- C57BL/6J Task Force 1996-1998
- Assistants Review Committee 1994-1998
- Recombinant DNA Committee 1994

Publications

Refereed Journal Articles

- A. A. Bushway and D. V. Serreze. Differences in the pH and iron content of chicken white and dark meat that effect the action of nitrite against aerobes. *Canadian Institute of Food Science and Technology Journal* 17:214, 1984.
- P. W. Reno, D. V. Serreze, S. K. Hellyer, and B. L. Nicholson. Hematological and physiological effects of Viral Erythrocytic Necrosis (VEN) in Atlantic Cod (*Gadus morhua*) and herring (*Clupea harengus*). *Fish Pathology* 20:353, 1985.
- A. A. Bushway, D. V. Serreze, D. F. McGann, R. H. True, T. M. Work, and R. J. Bushway. Effect of processing method and storage time on the nutrient composition of fiddlehead greens. *J. Food Science* 50:1491, 1985.
- C. E. Moody, D. V. Serreze, and P. W. Reno. Non-specific cytotoxic activity of teleost leukocytes. *Develop. and Comp. Immunol.* 9:51, 1985.
- M. Prochazka, E. H. Leiter, D. V. Serreze, and D. L. Coleman. Three recessive loci required for insulin dependent diabetes in Non-Obese Diabetic mice. *Science* 237:286, 1987.
- D. V. Serreze, E. H. Leiter, S. M. Worthen, and L. D. Shultz. NOD marrow stem cells adoptively transfer diabetes to resistant (NODxNON)F1 mice. *Diabetes* 37:252, 1988.
- D. V. Serreze, E. H. Leiter, E. L. Kuff, P. Jardieu, and K. Ishizaka. Molecular mimicry between insulin and retroviral antigen p73; development of cross reactive autoantibodies in sera of NOD and C57BL/KsJ-*db/db* mice. *Diabetes* 37:351, 1988.
- D. V. Serreze and E. H. Leiter. Defective activation of T suppressor cell function in Non-Obese Diabetic mice: potential relation to cytokine deficiencies. *J. Immunol.* 140:3801, 1988.
- M. Prochazka, D. V. Serreze, S. M. Worthen, and E. H. Leiter. Genetic control of diabetogenesis in NOD/Lt mice: development and analysis of cogenic stocks. *Diabetes* 38:1446, 1989.

E. H. Leiter, G. J. Christianson, D. V. Serreze, A. T. Ting, and S. M. Worthen. MHC antigen induction by Interferon- γ on cultured mouse pancreatic β cells and macrophages: genetic analysis of strain differences and discovery of an "occult" class I-like antigen in NOD/Lt mice. *J. Exp. Med.* 170:1243, 1989.

D. V. Serreze, K. Hamaguchi, and E. H. Leiter. Immunostimulation circumvents diabetes in NOD/Lt mice. *J. Autoimmunity* 2:759 1989.

D. V. Serreze, E. H. Leiter, and L. D. Shultz. Transplantation analysis of beta cell destruction in (NODxCBA)F1 bone marrow chimeras. *Diabetologia* 33:84, 1990.

D. V. Serreze and E. H. Leiter. Development of diabetogenic T cells from NOD/Lt marrow is blocked when an allo-H-2 haplotype is expressed on cells of hematopoietic origin, but not on thymic epithelium. *J. Immunol.* 147:1222, 1991.

M. Prochazka, D. V. Serreze, W. N. Frankel, and E. H. Leiter. NOR/Lt: H-2 matched, diabetes resistant control strain for NOD. *Diabetes* 41:98, 1992.

I. C. Gerling, D. V. Serreze, S. W. Christianson, and E. H. Leiter. Intrathymic islet cell transplantation reduces beta-cell autoimmunity and prevents diabetes in NOD/Lt mice. *Diabetes* 41:1672, 1992.

H. R. Gaskins, M. Prochazka, K. Hamaguchi, D. V. Serreze, and E. H. Leiter. Genetic and molecular association of endogenous xenotropic retroviruses with diabetogenesis in NOD/Lt mice. *J. Clin. Invest.*, 90:2220, 1992.

D. V. Serreze, H. R. Gaskins, and E. H. Leiter. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. *J. Immunol.*, 150:2534, 1993.

M. J. Rapaport, D. Zipris, A. H. Lazarus, A. Jaramillo, D. V. Serreze, E. H. Leiter, P. Cyopick, and T. L. Delovitch. Thymic T cell proliferative unresponsiveness in autoimmune NOD mice. II. IL-4 reverses NOD thymic T cell anergy and prevents the onset of diabetes. *J. Exp. Med.*, 178:87, 1993.

D. V. Serreze, J. W. Gaedeke, and E. H. Leiter. Hematopoietic stem cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. *Proc. Natl. Acad. Sci. USA*, 90:9625, 1993.

W. Hao, D. V. Serreze, D. K. McCulloch, J. L. Neifing, and J. P. Palmer. Insulin (auto)antibodies from human IDDM cross-react with retroviral antigen p73. *J. Autoimmunity*, 6:787, 1993.

D. V. Serreze, E. H. Leiter, G. J. Christianson, D. Greiner, and D. C. Roopenian. MHC class I deficient NOD-*B2m*^{null} mice are diabetes and insulinitis resistant. *Diabetes*, 43:505, 1994.

D. V. Serreze, M. Prochazka, P. C. Reifsnyder, M. Bridgett, and E. H. Leiter. Use of recombinant congenic and congenic strains of NOD mice to identify a new insulin dependent diabetes resistance gene. *J. Exp. Med.*, 180:1553, 1994.

T. N. M. Schumacher, D. V. Kantesaria, D. V. Serreze, D. C. Roopenian, and H. L. Ploegh. Transporters from *H-2^b*, *H-2^d*, *H-2^s*, *H-2^k*, and *H-2^g* (NOD/Lt) haplotype translocate similar sets of peptides. *Proc. Natl. Acad. Sci. USA*, 91:13004, 1994.

M. A. McAleer, P. Reifsnyder, S. M. Palmer, M. Prochazka, J. M. Love, J. B. Copeman, E. E. Powell, N. R. Rodrigues, Jan-Bas Prins, D. V. Serreze, N. H. DeLarto, L. S. Wicker, L. B. Peterson, N. J. Schork, J. A. Todd, and E. H. Leiter. Crosses of NOD Mice with the Related NON Strain: A Polygenic Threshold Model for Type I Diabetes. *Diabetes*, 44:1186, 1995.

D. V. Serreze, E. H. Leiter, M. S. Hanson, S. W. Christianson, L. D. Shultz, R. M. Hesselton and D. L. Greiner. *Emv30*^{null} NOD-*scid* mice: an improved host for adoptive transfer of autoimmune diabetes and growth of human lymphohematopoietic cells. *Diabetes*, 44:1392, 1995.

D. V. Serreze, S. Gallichin, D. P. Snider, K. Croitoru, K. L. Rosenthal, E. H. Leiter, G. J. Christianson, M. E. Dudley, and D. C. Roopenian. MHC class I mediated antigen presentation and induction of CD8⁺ cytotoxic T lymphocyte responses in autoimmune diabetes prone NOD mice. *Diabetes*, 45:902, 1996.

M. S. Hanson, M. Cetkovic-Cvrlje, V. K. Ramiya, M. A. Atkinson, N. K. MacLaren, B. Singh, J. F. Elliott, D. V. Serreze, and E. H. Leiter. Quantitative thresholds of MHC class II I-E expressed on hematopoietically derived APC in transgenic NOD/Lt mice determine level of diabetes resistance and indicate mechanism of protection. *J. Immunol.*, 157:1279, 1996.

D. V. Serreze, H. D. Chapman, D. S. Varnum, M. S. Hanson, P. C. Reifsnyder, S. D. Richard, S. A. Fleming, E.H. Leiter, and L. D. Shultz. B lymphocytes are essential for the initiation of T cell mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.*Igμ*^{null} mice. *J. Exp. Med.*, 184:2049, 1996.

D. V. Serreze, H. D. Chapman, I. Gerling, E. H. Leiter, and L. D. Shultz. Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent. *J. Immunol.*, 158:3978, 1997.

E.H. Leiter, H. Tsumura, D. V. Serreze, H. D. Chapman, D. U. Rabin, M. S. Lan, and A. L. Notkins. Mapping to Chromosomes 1 and 12 of mouse homologs of human protein tyrosine phosphatase, receptor-type, related genes encoding pancreatic beta cell autoantigens. *Mammalian Genome*, 8:949, 1997.

D. V. Serreze, M. Bridgett, H. D. Chapman, E. Chen, S. D. Richard, and E. H. Leiter. Subcongenic analysis of the *Idd13* locus in NOD/Lt mice: evidence for several susceptibility genes including a possible diabetogenic role for β 2-microglobulin. *J. Immunol.*, 160:1472, 1998.

R. Jiang, Y. Lan, H. D. Chapman, C. Shawber, C. R. Norton, D. V. Serreze, G. Weinmaster, and T. Gridley. Defects in limb, craniofacial and thymic development in *Jagged2* mutant mice. *Genes and Development*, 12:1046, 1998.

D. V. Serreze, S. A. Fleming, H. D. Chapman, S. D. Richard, E. H. Leiter, and R. M. Tisch. B-lymphocytes are critical antigen presenting cells for the initiation of T cell mediated autoimmune diabetes in NOD mice. *J. Immunol.*, 161:3912, 1998.

T. P. DiLorenzo, R. T. Graser, T. Ono, G. J. Christianson, H. D. Chapman, D. C. Roopenian, S. G. Nathenson, and D. V. Serreze. MHC class I-restricted T cells are required for all but the end stages of diabetes development in NOD mice and utilize a prevalent T cell receptor α chain gene rearrangement. *Proc. Natl. Acad. Sci. USA*, 95:12538, 1998.

T. G. Markees, D. V. Serreze, N. E. Phillips, C. H. Sorli, E. J. Gordon, L. D. Shultz, R. J. Noelle, B. A. Woda, D. L. Greiner, J. P. Mordes, and A. A. Rossini. NOD mice have a generalized defect in their response to transplantation tolerance induction. *Diabetes*, 48:967, 1999.

R. T. Graser, C. E. Mathews, E. H. Leiter, and D. V. Serreze. MHC characterization of ALR and ALS mice: respective similarities to the NOD and NON strains. *Immunogenetics*, 49:722, 1999.

R. Tisch, B. Wang, and D. V. Serreze. Induction of GAD65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope-dependent. *J. Immunol.*, 163:1178, 1999.

S. Trembleau, G. Penna, S. Gregori, H. Chapman, D. Serreze, J. Magram, and L. Adorini. Pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice. *J. Immunol.*, 163:2960, 1999.

C. E. Mathews, R. T. Graser, D. V. Serreze, and E. H. Leiter. Re-evaluation of the major histocompatibility complex genes of the NOD-progenitor CTS/Shi strain. *Diabetes*, 49:131, 2000.

R. T. Graser, T. P. DiLorenzo, F. Wang, G. J. Christianson, H. D. Chapman, D. C. Roopenian, S. G. Nathenson, and D. V. Serreze. Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions. *J. Immunol.*, 164:3913, 2000.

D. V. Serreze, E. W. Ottendorfer, T. M. Ellis, C. J. Gauntt, and M. A. Atkinson. Acceleration of type I diabetes by a coxsackievirus infection requires a preexisting critical mass of autoreactive T cells in pancreatic islets. *Diabetes*, 49:708, 2000.

D. V. Serreze, C. M. Post, H. D. Chapman, E. A. Johnson, B. Lu, and P. B. Rothman. Interferon- γ receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. *Diabetes*, 49:2007, 2000.

C. E. Mathews, R. T. Graser, A. Savinov, D. V. Serreze and Edward H. Leiter. Unusual resistance of ALR/Lt beta cells to autoimmune destruction: role for beta cell expressed resistance determinants. *Proc. Natl. Acad. Sci. USA*, 98:235, 2001.

D. V. Serreze, H. D. Chapman, C. M. Post, E. A. Johnson, W. L. Suarez-Pinzon, and A. Rabinovitch. Th1 to Th2 cytokine shifts in NOD mice: sometimes an outcome, rather than the cause of diabetes resistance elicited by immunostimulation. *J. Immunol.*, 166:1352, 2001.

R. Tisch, B. Wang, D. J. Weaver, B. Liu, T. Bui, J. Arthos, and D. V. Serreze. Antigen-specific mediated suppression of β cell autoimmunity by plasmid DNA vaccination. *J. Immunol.* 166:2122, 2001.

P. P. L. Chiu, D. V. Serreze, and J. S. Danska. Development and function of diabetogenic T cells in B cell deficient non-obese diabetic mice. *Diabetes* 50:763, 2001.

S. Efrat, D. Serreze, A. Svetlanov, C. M. Post, E. A. Johnson, K. Herold, and M. Horwitz. Adenovirus early region 3 (E3) immunomodulatory genes prevent autoimmune diabetes in nonobese diabetic (NOD) mice. *Diabetes*, 50:980, 2001.

R. Tisch, B. Wang, M. A. Atkinson, D. V. Serreze, and R. Friedline. A glutamic acid decarboxylase 65-specific Th2 T cell clone immunoregulates autoimmune diabetes in nonobese diabetic mice. *J. Immunol.* 166:6925, 2001.

E. A. Johnson, P. Silveira, H. D. Chapman, E. H. Leiter, and D. V. Serreze. Inhibition of autoimmune diabetes in NOD mice by transgenic restoration of H2-E

MHC class II expression: additive, but unequal involvement of multiple APC subtypes. *J. Immunol.* 167:2404, 2001.

D. V. Serreze, E. A. Johnson, H. D. Chapman, R. T. Graser, M. P. Marron, T. P. DiLorenzo, Y. Yoshimura, S. G. Nathenson, and S. Joyce. Autoreactive diabetogenic T cells in NOD mice can efficiently expand from a greatly reduced precursor pool. *Diabetes*, 50:1992, 2001.

E. E. Hamilton-Williams, D. V. Serreze, B. Charlton, E. A. Johnson, M. P. Marron, A. Mullbacher, and R. M. Slattery. Transgenic rescue implicates β 2-Microglobulin as a diabetes susceptibility gene in NOD mice. *Proc. Natl. Acad. Sci. USA*, 98:11533, 2001.

E. Bonifacio, M. Atkinson, G. Eisenbarth, D. Serreze, T. W. H. Kay, E. Lee-Chan, and B. Singh. International workshop on lessons from animal models for human type 1 diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in Non-Obese Diabetic mice. *Diabetes*, 50:2451, 2001.

E. Bonifacio, M. Atkinson, G. Eisenbarth, D. Serreze, T. W. H. Kay, E. Lee-Chan, and B. Singh. Analyzing target antigens of humoral autoimmunity in nonobese diabetic mice. *Ann. NY Acad. Sci.* 958:1, 2002.

M. P. Marron, R. T. Graser, H. D. Chapman, and D. V. Serreze. Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice. *Proc. Natl. Acad. Sci. USA*, 99:13753, 2002.

T. P. DiLorenzo, S. M. Lieberman, T. Takaki, S. Honda, H. D. Chapman, P. Santamaria, D. V. Serreze, and S. G. Nathenson. During the early prediabetic period in NOD Mice, the pathogenic CD8⁺ T cell population comprises multiple antigenic specificities. *Clinical Immunol.*, 105:332, 2002.

P. A. Silveira, E. A. Johnson, H. D. Chapman, T. Bui, R. M. Tisch and D. V. Serreze. The preferential ability of B Lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen specific immunoglobulin receptors. *Eur. J. Immunol.*, 32:3657, 2002.

T. Pearson, T. G. Markees, L. S. Wicker, D. V. Serreze, L. B. Peterson, J. P. Mordes, A. A. Rossini, and D. L. Greiner. NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. *Diabetes*, 52:321, 2003.

D. V. Serreze, M. A. Pierce, C. M. Post, H. D. Chapman, H. Savage, R. T. Bronson, P. B. Rothman, and G. A. Cox. Paralytic autoimmune myositis develops in NOD mice made Th1 cytokine deficient by expression of an IFN γ receptor β chain transgene. *J. Immunol.*, 170:2742, 2003.

M. A. Pierce, H. D. Chapman, C. M. Post, A. Svetlanov, S. Efrat, M. Horwitz and D. V. Serreze. Adenovirus Early Region 3 (E3) Anti-Apoptotic 10.4K, 14.5K, and 14.7K Genes Decrease the Incidence of Autoimmune Diabetes in NOD Mice. *Diabetes*, 52:1119, 2003.

J-S. Mo, M. G. Anderson, M. Gregory, R. S. Smith, O. V. Savinova, D. V. Serreze, B. R. Ksander, J. W. Steilein, and S. W. M. John. By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma. *J. Exp. Med.*, 197:1335, 2003.

T. Pearson, T. G. Markees, D. V. Serreze, M. A. Pierce, M. P. Marron, L. S. Wicker, L. B. Peterson, L. D. Shultz, J. P. Mordes, A. A. Rossini and D. L. Greiner. Genetic disassociation of autoimmunity and resistance to costimulation blockade-induced transplantation tolerance in NOD Mice. *J. Immunol.*, 171:185, 2003.

S. M. Lieberman, A. M. Evans, B. Han, T. Takaki, Y. Vinnitskaya, J. A. Caldwell, D. V. Serreze, J. Shabanowitz, D. F. Hunt, S. G. Nathenson, P. Santamaria, and T. P. DiLorenzo. Identification of the novel β cell antigen targeted by a prevalent population of pathogenic CD8 T cells in autoimmune diabetes. *Proc. Natl. Acad. Sci. USA*, 100:8384, 2003.

C. E. Mathews, R. T. Graser, R. Bagley, J. Caldwell, D. V. Serreze, and E. H. Leiter. Genetic analysis of resistance to type 1 diabetes in ALR/Lt mice, an NOD-related strain with systemic defenses against autoimmune-mediated diabetogenic stress. *Immunogenetics*, 55:491, 2003.

D. V. Serreze, T. M. Holl, M. P. Marron, R. T. Graser, E. A. Johnson, C. Choisy-Rossi, R. M. Slattery, S. M. Lieberman, and T. P. DiLorenzo. MHC class II molecules play a role in the selection of autoreactive class I restricted CD8 T cells that are essential contributors to type 1 diabetes development in NOD mice. *J. Immunol.*, 172:871, 2004.

P. A. Silveira, J. Dombrowsky, E. Johnson, H. D. Chapman, D. Nemazee, and D. V. Serreze. Defects in B cell selection underlie the development of diabetogenic antigen presenting cells in NOD mice. *J. Immunol.*, 172:5086, 2004.

T. Takaki, S. M. Lieberman, T. M. Holl, B. Han, P. Santamaria, D. V. Serreze, and Teresa P. DiLorenzo. Requirement for both H-2D^b and H-2K^d for the

induction of diabetes by the promiscuous CD8⁺ T cell clonotype AI4. *J. Immunol.*, 173:2530, 2004.

T. Pearson, P. Weiser, T. G. Markees, D. V. Serreze, L. S. Wicker, L. B. Peterson, A-M. Cumisky, L. D. Shultz, J. P. Mordes, A. A. Rossini, and D. L. Greiner. Islet allograft survival induced by costimulation blockade in NOD mice is controlled by allelic variants of *Idd3*. *Diabetes*, 53:1972, 2004.

C-M. Choisy-Rossi, T. M. Holl, M. A. Pierce, H. D. Chapman, and D. V. Serreze. Enhanced pathogenicity of diabetogenic T cells escaping a non-MHC gene controlled near death experience. *J. Immunol.*, 173:3791, 2004.

F. Fallarino, R. Bianchi, C. Orabona, C. Vacca, M. L. Belladonna, M. C. Fioretti, D. V. Serreze, U. Grohman, and P. Puccetti. CTLA-4-Ig activates Forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. *J. Exp. Med.*, 200:1051, 2004.

S. M. Lieberman, T. Takaki, B. Han, P. Santamaria, D. V. Serreze, and T. P. DiLorenzo. Individual NOD mice exhibit unique patterns of CD8 T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophin myotonia kinase. *J. Immunol.*, 173:6727, 2004.

M. A. Pierce, A. Svetlanov, M. S. Horwitz, and D. V. Serreze. Prevention of Autoimmune diabetes in NOD Mice by beta cell expression of adenovirus early region 3 transgenes: effects of deleting AdE3-11.6K (Adenovirus Death Protein). *J. Virol.*, 79:619, 2005.

D. V. Serreze, E. W. Ottendorfer, C. Wasserfall, M. A. Pierce, T. M. Ellis, Mark A. Atkinson. Diabetes acceleration or prevention by coxsackie virus infection; critical requirements for both interleukin-4 and interferon gamma. *J. Virol.*, 79:1045, 2005.

E. J. Gordon, L. S. Wicker, L. B. Peterson, D. V. Serreze, T. G. Markees, L. D. Shultz, A. A. Rossini, D. L. Greiner, and J. P. Mordes. Autoimmune diabetes and resistance to xenograft transplantation tolerance in NOD mice. *Diabetes*, 54:107, 2005.

Y-G. Chen, C-M. Choisy-Rossi, T. M. Holl, H. D. Chapman, G. S. Besra, S. A. Porcelli, S. B. Wilson, and D. V. Serreze. Autoimmune diabetes prevention by NKT-cell activation involves tolerogenic recruitment of both dendritic cells and pathogenic T cells to pancreatic lymph nodes. *J. Immunol.*, 174:1196, 2005.

D. P. Pomerleau, R. J. Bagley, T. M. Holl, D. V. Serreze, C. E. Mathews, and E. H. Leiter. MHC-linked diabetes susceptibility in NOD/Lt mice: subcongenic

analysis localizes a component of "Idd16" at the H2-D end of the diabetogenic H2⁹⁷ complex. *Diabetes*, 54:1603, 2005.

B-Y. Xu, H. Yang, D. V. Serreze, R. MacIntosh, W. Yu, and J. R. Wright. Rapid destruction of encapsulated islet xenografts by NOD mice is CD4 dependent and facilitated by B cells: innate immunity and autoimmunity do not play significant roles. *Transplantation*, 80:402, 2005.

P. C. Reifsnyder, R. Li, P. Silveira, G. Churchill, D. V. Serreze, and E. H. Leiter. Conditioning the genome identifies additional diabetes resistance loci in type diabetes resistant NOR/Lt mice. *Genes and Immunity*, 6:528, 2005.

C-H Lee, Y-G Chen, J. Chen, P. C. Reifsnyder, D. V. Serreze, M. Clare-Salzler, M. Rodriguez, C. Wasserfall, M. A. Atkinson, and E. H. Leiter. Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression. II. Immunological analyses. *Diabetes*, 55:171, 2006.

T. Takaki, M. P. Marron, C. E. Mathews, S. T. Guttman, R. Bottino, M. Trucco, T. P. DiLorenzo, and D. V. Serreze. HLA-A*201-restricted T cells contributing to type 1 diabetes in "humanized" mice are cytotoxic to human pancreatic β cells, and identify autoantigens with potential clinical relevance. *J. Immunol.*, 176:3257, 2006.

J. Chen, Y-G Chen, P. C. Reifsnyder, W. H. Schott, C-H Lee, F. Scheuplein, F. Haag, F. Koch-Nolte, D. V. Serreze, and E. H. Leiter. Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an Art-2 dependent fashion. *J. Immunol.*, 176:4590, 2006.

Y-G. Chen, J. Chen, M. A. Osborne, H. D. Chapman, G. S. Besra, S. A. Porcelli, S. B. Wilson, E. H. Leiter, and D. V. Serreze. CD38 is required for the peripheral survival of immunotolerogenic CD4⁺ iNKT cells in NOD mice. *J. Immunol.*, 177:2939, 2006.

P. A. Silveira, H. D. Chapman, J. Stolp, E. Johnson, S. L. Cox, K. Hunter, L. Wicker, and D. V. Serreze. Genes within the *Idd5* and *Idd9/11* diabetes susceptibility loci affect the pathogenic activity of B-cells in NOD mice. *J. Immunol.*, 177:7033, 2006.

D. V. Serreze, M. A. Osborne, Y-G. Chen, H. D. Chapman, T. Pearson, and D. L. Greiner. Partial versus full allogeneic hematopoietic chimerization is a preferential means to inhibit type 1 diabetes as the latter induces generalized immunosuppression. *J. Immunol.*, 177:6675, 2006.

R. Razavi, Y Chan, F. N. Afifiyan, X. J. Liu, X. Wan, J. Yantha, H. Tsui, L. Tang, S. Tsai, P. Santamaria, J. P. Driver, D. Serreze, M. W. Salter and

H.-M. Dosch. TRPV1+ sensory neurons control β -cell stress and islet inflammation in autoimmune diabetes. *Cell*, 127:1123, 2006.

Y-G Chen, P. A. Silveira, M. A. Osborne, H. D. Chapman, and D. V. Serreze. Cellular expression requirements for inhibition of type 1 diabetes by a dominantly protective MHC haplotype. *Diabetes*, 56:424, 2007.

J. Yamanouchi, D. Rainbow, P. Serra, S. Howlett, K. Hunter, V. E.S. Garner, A. Gonzalez-Munoz, J. Clark, R. Veijola, R. Cubbon, S-L. Chen, R. Rosa, A. M. Cumiskey, D. V. Serreze, S. Gregory, J. Rogers, P. A. Lyons, B. Healy, L. J. Smink, J. A. Todd, L. B. Peterson, L. S. Wicker and P. Santamaria. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. *Nature Genetics*, 39:329, 2007.

Y-G. Chen, J. P. Driver, P. A. Silveira, and D. V. Serreze. Subcongenic analysis of genetic basis for impaired development of invariant NKT cells in NOD mice. *Immunogenetics*, 59:705, 2007.

I. Jarchum, J. C. Baker, T. Yamada, T. Takaki, M. P. Marron, D. V. Serreze, and T. P. DiLorenzo. In vivo cytotoxicity of insulin-specific CD8 T cells in HLA-A201-transgenic NOD mice. *Diabetes*, 56:2551, 2007.

J. P. Driver, O. Foreman, C. Mathieu, E. van Etten, and D. V. Serreze. Comparative Therapeutic Effects of Orally Administered 1,25-Dihydroxyvitamin D3 and 1 α -hydroxyvitamin D3 on Type-1 Diabetes in NOD mice fed a normal-calcaemic diet. *Clin. Exp. Immunol.*, 151:76, 2008.

D. V. Serreze, C. Choisy-Rossi, A. Grier, T. M. Holl, H. D. Chapman, J. R. Gahagan, M. A. Osborne, W. Zhang, B. L. King, A. Brown, D. Roopenian, and M. P. Marron. Through regulation of TCR expression levels, an *Idd7* region gene(s) interactively contributes to the impaired thymic deletion of autoreactive diabetogenic CD8 T-cells in NOD mice. *J. Immunol.*, 180:3250, 2008.

R. J. Chaparro, A. R. Burton, D. V. Serreze, D. A. Vignali, and Teresa P. DiLorenzo. In vitro expansion of retrogenic T-cells for the rapid identification of MHC class I-restricted antigens relevant to autoimmune diabetes. *J. Immunol. Methods*, 335:106, 2008.

A. Mukhopadhyaya, T. Hanafusa, I. Jarchum, Y-G. Chen, D. V. Serreze, R. M. Steinman, K. V. Tarbell, and Teresa P. DiLorenzo. In vivo targeting of dendritic cells with β cell antigen leads to deletion of autoreactive CD8⁺ T-cells in NOD mice. *Proc. Natl. Acad. Sci. USA*, 105:6374, 2008.

Y-G. Chen, F. Scheuplein, M. A. Osborne, H. D. Chapman, and D. V. Serreze. The *Idd9/11* genetic locus regulates diabetogenic activity of CD4 T-cells in non-obese diabetic (NOD) mice. *Diabetes*, 57:3273, 2008.

J. Mangada, T. Pearson, M. A. Brehm, L. S. Wicker, L. B. Peterson, L. D. Shultz, D. V. Serreze, A. A. Rossini, and D. L. Greiner. *Idd* loci synergize to prolong islet allograft survival induced by costimulation blockade in NOD mice. *Diabetes*, 58:165, 2009.

F. Scheuplein, B. Rissiek, J. P. Driver, Y-G. Chen, F. Koch-Nolte, and David V. Serreze. A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes. *J. Autoimmunity*, 34:145, 2010.

J. P. Driver, F. Scheuplein, Y-G. Chen, A. E. Grier, S. B. Wilson, and D. V. Serreze. iNKT-cell activation for autoimmune diabetes prevention-a dendritic cell genetic decision of a silver bullet or Russian roulette? *Diabetes*, 59:423, 2010.

A. Strom, B. Sonier, H. D. Chapman, M. Mojibian, G. S. Wang, C. R. Slatculescu, D. V. Serreze, and F. W. Scott. Peripherin-reactive antibodies in mouse, rabbit, and human blood. *J. Proteome Res.*, 9:1203, 2010.

S. L. Cox, J. Stolp, D. V. Serreze, A. Basten, and P. A. Silveira. Enhanced responsiveness to T cell help causes loss of B cell tolerance to a pancreatic β cell neo-self antigen in type-1 diabetes prone NOD mice. *Eur. J. Immunol.*, 40:3413, 2010.

E. I. Rivas, J. P. Driver, M. N. Garabatos, M. Presa, C. Mora, F. Rodriguez, D. V. Serreze, and T. Stratmann. Targeting of a T Cell Agonist Peptide to Lysosomes by DNA Vaccination Induces Tolerance in the Non-Obese Diabetic Mouse. *J. Immunol.*, 186:4078, 2011.

Y-G. Chen, F. Scheuplein, A. A. Hewes, P. C. Reifsnyder, E. H. Leiter, and D. V. Serreze. Testing the role of P2X7 receptors in the development of type 1 diabetes in NOD mice. *J. Immunol.*, 186:4278, 2011.

M. Niens, A. E. Grier, M. Marron, D. L. Greiner, and D. V. Serreze. Prevention by multi-peptide coupled-cells of "humanized" diabetogenic CD8 T-cell responses in HLA transgenic NOD mice. *Diabetes*, 60:1229, 2011.

J. P. Driver, Y-G. Chen, W. Zhang, S. Asrat, and D. V. Serreze. Unmasking genes in a type 1 diabetes resistant mouse strain that enhance the peripheral activation of pathogenic CD8 T-cells. *Diabetes*, 60:1354, 2011.

D. V. Serreze, H. D. Chapman, M. Niens, R. Dunn, J. P. Driver, M. Haller, C. Wasserfall, and M. A. Atkinson. Loss of intra-islet CD20 expression may complicate efficacy of B-lymphocyte directed type 1 diabetes therapies. *Diabetes*, 60:2914, 2011.

J. P. Driver, D. J. Lamont, C. Gysemans, C. Mathieu, and D. V. Serreze. Calcium insufficiency accelerates type 1 diabetes in vitamin D receptor deficient NOD mice. *Endocrinology*, 152:4620, 2011.

Y-G. Chen, S-W Tsaih, and D. V. Serreze. Genetic control of murine invariant natural killer T-cell development dynamically differs dependent on the examined tissue type. *Genes and Immunity*, 13:164, 2012.

L. P. Bogdanik, H. D. Chapman, K. E. Miers, D. V. Serreze, and R. W. Burgess. Hastened neuromuscular junction maturation, sensory and behavioral phenotypes in a new *GlyT2* mouse mutation. *PlosOne*, 7:e30217, 2012.

J. Stolp, Y-G. Chen, S. L. Cox, V. Henck, W. Zhang, S-W Tsaih, H. Chapman, T. Stearns, D. V. Serreze and P. A. Silveira. Subcongenic analyses reveal complex interactions between distal Chromosome 4 genes controlling diabetogenic B cells and CD4 T cells in NOD mice. *J. Immunol.*, 189:1406, 2012.

J. K. Lee, L. Scanduzzi, A. Ray, J. Wei, K. A. Hofmeyer, Y. M. Abadi, P. Loke, J. Lin, J. Yuan, D. V. Serreze, J. P. Allison, and X. Zang. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. *J. Immunol.*, 189:4165, 2012.

W. Unger, T. Pearson, J. R. F. Abreu, S. Laban, A. R. van der Slik, S. Mulder-van der Kracht, M. G. D. Kester, D. V. Serreze, L. D. Shultz, M. Griffioen, J. Wouter Drijfhout, D. L. Greiner, and B. O. Roep. Human islet-specific CTLs cloned from an individual with type 1 diabetes cause beta-cell destruction following engraftment into HLA-A2 transgenic NOD/SCID/IL2RG^{null} mice. *PLoSOne*, 7:e49213, 2012.

G. Mukherjee, A. Geliebter, J. Babad, P. Santamaria, D. V. Serreze, G. J. Freeman, K. V. Tarbell, A. Sharpe, and T. P. DiLorenzo. DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8 T cells independently of PD-1 and PD-L1. *Int. Immunol.* 25:651, 2013.

M. Presa, N. Garabatos, A. Z. Ortiz, C. Izquierdo, L. Teyton, C. Mora, D. Serreze*, and T. Stratmann*. Impaired oral tolerance induction in diabetes prone but not diabetes resistant mice revealed by cholera toxin subunit B-peptide fusion proteins. *Eur. J. Immunol.*, 43:2969, 2013.

*Co-senior authors

N. Garabatos, R. Alvarez, J. Carrillo, J. Carrascal, H.D. Chapman, M. Presa, C. Mora, D. Serreze, J. Verdaguer, and T. Stratmann. In vivo detection of peripherin-specific autoreactive B cells during type 1 diabetes pathogenesis. *J. Immunol*, 192:3080, 2014.

D. Lamont[#], G. Mukherjee[#], P. R. Kumar, D. Samanta, C. G. McPhee, T. H. W. Kay, S. C. Almo, T. P. DiLorenzo^{*}, and D. V. Serreze^{*}. Compensatory mechanisms allow undersized anchor-deficient class I MHC ligands to mediate pathogenic autoreactive T-cell responses. *J. Immunol.*, 193:2135, 2014.

[#]Co-first authors, ^{*}Co-senior authors

S-W. Tsaih, M. Presa, S. Khaja, A. E. Ciecko, D. V. Serreze, and Y-G. Chen. A locus on mouse Chromosome 13 inversely regulates CD1d expression and the development of invariant natural killer T-cells. *Genes and Immunity*, 16:221, 2015.

P. Simecek, G. A. Churchill, H. Yang, L. B. Rowe, L. Herberg, D. V. Serreze, and E. H. Leiter. Genetic analysis of substrain divergence in NOD mice. *3G Genes / Genomes / Genetics*, 5:771, 2015.

M. Presa, Y-G. Chen, A. E. Grier, E. H. Leiter, M. A. Brehm, D. L. Greiner, L. D. Shultz, and D. V. Serreze. The presence and preferential activation of Tregs diminishes adoptive transfer of autoimmune diabetes by polyclonal NOD T cell effectors into NSG versus NOD-*scid* mice. *J. Immunol*, 195:3011, 2015.

F. Scheuplein, D. Lamont, M. Poynter, J. Boyson, D. Serreze, L. Lundblad, R. Marshal, and R. Schaub. Mouse invariant monoclonal antibody NKT14: a novel tool to manipulate iNKT cell function in vivo. *PLoS ONE*, 10:e0140729, 2015.

C. M. Leeth, J. Racine, H.D. Chapman, B. Arpa, J. Carrillo, J. Carrascal, Q. Wang, J. Ratiu, L. Egia-Mendikute, E. Rosell-Masea, T. Stratmann, J. Verdaguer, and D. V. Serreze. B-lymphocytes expressing an immunoglobulin specificity recognizing the pancreatic β -cell autoantigen peripherin are potent contributors to type 1 diabetes development in NOD mice. *Diabetes*, 65:1977, 2016.

T. I. Mahmoud, J. Wang, J. L. Karnell, Q. Wang, S. Wang, B. Naiman, P. Gross, P. Brohawn, C. Morehouse, J. Aoyama, C. Wasserfall, L. Carter, M. A. Atkinson, D. V. Serreze, H. Braley-Mullen, T. Mustelin, R. Kolbeck, R. Herbst and R. Ettinger. Autoimmune manifestations in aged mice arise from early-life immune dysregulation. *Science Translational Medicine*, 8:361ra137, 2016.

B. Lin^{*}, A. E. Ciecko^{*}, W. G. Wang, E. MacKinney, D. V. Serreze, and Y-G. Chen. Congenic mapping identifies a novel *Idd9* subregion regulating type 1 diabetes in NOD mice. *Immunogenetics*, 69:193, 2017.

*co-first authors

J. P. Driver*, J. Racine*, C. Y. Ye, D. J. Lamont, B. N. Newby, C. G. McPhee-Leeth, H. D. Chapman, T. M. Brusko, Y-G. Chen, C. E. Mathews, and D. V. Serreze. Interferon gamma limits diabetogenic CD8 T-Cell effector responses in type-1 diabetes. *Diabetes*, 66:710, 2017.

*co-first authors

J. J. Ratiu*, J. J. Racine*, M. G Hasham*, Q. Wang, J. A. Branca, H. D. Chapman, J. Zhu, N. Donghia, V. Philip, W. H. Schott, C. Wasserfall, M. A. Atkinson, K. D. Mills, C. M. Leeth, and D. V. Serreze. Genetic and small molecule disruption of the AID/RAD51 axis similarly protects NOD mice from type 1 diabetes through expansion of regulatory B-lymphocytes. *J. Immunol.* 198:4255, 2017.

*co-first authors

J. R. Fahey, B. Lyons, H. Olekszak, A. Mourino, J. Ratiu, J. Racine, H. Chapman, D. V. Serreze, D. Baker, and K. Hendrix. Antibiotic associated manipulation of gut microbiome and phenotypic restoration in NOD mice. *Comparative Medicine*, 67:335, 2017.

Q. Wang, J. J. Racine, J. J. Ratiu, S. Wang, R. Ettinger, C. Wasserfall, M. A. Atkinson, and D. V. Serreze. Transient BAFF blockade inhibits type 1 diabetes development in NOD mice by enriching immunoregulatory B-lymphocytes sensitive to deletion by anti-CD20 co-therapy. *J. Immunol.* 199:3757, 2017.

J. J. Racine, I. Stewart, J. Ratiu, G. Christianson, E. Lowell, K. Helm, J. Allocco, R. S. Maser, Y-G. Chen, C. M. Lutz, D. Roopenian, T. DiLorenzo, and D. V. Serreze. Improved murine-MHC-deficient HLA-Transgenic NOD-mouse models for T1D therapy development. *Diabetes*, 67:923, 2018.

J. Schloss, R. Ali, J. J. Racine, Harold D. Chapman, D. V. Serreze, and T. P. DiLorenzo. HLA-B*39:06 efficiently mediates type 1 diabetes in a mouse model incorporating reduced thymic insulin expression. *J. Immunol.*, 200:3353, 2018.

M. Presa*, J. Racine*, J. Dwyer, D. J. Lamont, J. Ratiu, V. K. Sarsani, Y-G. Chen, A. Geurts, I. Schmitz, T. Stearns, J. Allocco, H. Chapman, and D. V. Serreze. A hypermorphic *Nfkbid* allele contributes to impaired thymic deletion of autoreactive diabetogenic CD8⁺ T-cells in NOD mice. *J. Immunol.*, 201:1907, 2018.

A. M. Sandor, R. S. Lindsay, N. Dyjack, J. C. Whitesell, C. Rios, B. J. Bradley, K. Haskins, D. V. Serreze, A. M. Geurts, Y-G. Chen, M. A. Seibold, J. Jacobelli, and R. S. Friedman. CD11c⁺ cells are gatekeepers for lymphocyte trafficking to infiltrated islets during type 1 diabetes. *Frontiers in Immunology*, 10:99, 2019.

M. H. Forsberg, B. Foda, D. V. Serreze, and Y-G Chen. Combined congenic mapping and nuclease-based gene targeting for studying allele-specific effects of *Tnfrsf9* within the *Idd9.3* autoimmune diabetes locus. *Scientific Reports*, 9:4316, 2019.

J. Verdaguer-Autonell, L. Egia-Mendikute, B. Arpa-Puigdemont, E. Rossel-Mases, M. Corral-Pujol, J. Carrascal-Sánchez, J. Ca. Molina, C. Mora-Giral, H. Chapman, A. Panosa, Marta Vives-Pi, T. Stratmann, and D. Serreze. B-lymphocyte phenotype determines T-lymphocyte subset differentiation in autoimmune diabetes. *Frontiers in Immunology*, 10:1732, 2019.

A. E. Ciecko, B. Foda, J. Y. Barr, S. Ramanathan, M. A. Atkinson, D. V. Serreze, A. M. Geurts, S. M. Lieberman, and Y-G. Chen. Interleukin 27 is essential for type 1 diabetes development and Sjögren syndrome-like manifestations. *Cell Reports*, 29:3073, 2019.

A. S. DeGroot, G. Skowron, J. R. White, C. Boyle, G. Richard, D. Serreze, and W. D. Martin. Therapeutic administration of Tregitope-human albumin fusion with insulin peptides promote antigen-specific adaptive tolerance induction. *Scientific Reports* 9:16103, 2019.

J. J. Wright, D. C. Saunders, C. Dai, G. Poffenberger, B. Cairns, D. V. Serreze, D. H. Harlan, R. Bottino, M. Brissova, and A. C. Powers. Decreased pancreatic acinar cell number in type 1 diabetes. *Diabetologia*, 63:1418, 2020.

B. Foda, A. E. Ciecko, D. V. Serreze, W. M. Ridgway, A. M. Geurts, and Y-G. Chen. CD137 ligand is important for type 1 diabetes development but dispensable for the homeostasis of disease suppressive CD137⁺ FoxP3⁺ regulatory CD4 T-cells. *J. Immunology*, 204:2887, 2020.

C. Ye, M. Wiles, B. Low, T. Brusko, D. V. Serreze, and J. P. Driver. CD70 inversely regulates Tregs and iNKT cells and modulates type 1 diabetes in NOD mice. *J. Immunol.*, 205:1763, 2020.

M. Shapiro, W-I. Yeh, J. R. Longfield, J. Gallagher, C. M. Infante, S. Wellford, A. Posgai, M. A. Atkinson, M. Campbell-Thompson, S. M. Lieberman, D. Serreze, A. Geurts, Y-G. Chen, and T. M. Brusko. CD226 deletion reduces type 1 diabetes in the NOD mouse by impairing thymocyte development and peripheral T cell activation. *Frontiers in Immunology*, fimmu.2020.0218.

J. J. Racine, H. D. Chapman, R. Doty, B. M. Cairns, T. J. Hines, A. L. D. Tadenev, L. C. Anderson, T. Green, M. E. Dyer, J. M. Wotton, Z. Bichler, J. K. White, R. Ettinger, R. W. Burgess, and D. V. Serreze. T-cells from NOD-*Perlg*

mice target both pancreatic and neuronal tissue. *J. Immunol.*, 205:2026, 2020.
(featured on cover)

I. L. Debrezni, M. S. Chimenti, D. V. Serreze, A. M. Geurts, Y-G Chen, and S. M. Lieberman. Toll-like receptor 7 is required for lacrimal autoimmunity and type 1 diabetes development in Nonobese Diabetic Mice. *Int. J. Mol. Sci.* 21(24), 2020.

T. J. Break, V. Oikonomou, N. Dutzan, J. V. Desai, T. Freiwald, D. Chauss, O. J. Harrison, J. Alejo, D. W. Williams, S. Pittaluga, C-C. R. Lee, N. Bouladoux, M. Swamydas, K. W. Hoffman, T. Greenwell-Wild, V. M. Bruno, L. B. Rosen, W. Lwin, A. Renteria, S. M. Potejo, J. A. Shannon, I. A. Myles, P. Olbrich, E. R. N. Ferre, M. Schmitt, D. Martin, D. L. Barber, M. Swidergall, N. V. Solis, S. G. Filler, L. D. Notarangelo, D. V. Serreze, M. Matsumoto, H. D. Hickman, P. M. Murphy, M. S. Anderson, J. K. Lim, S. M. Holland, B. Afzali, Y. Belkaid, N. M. Moutsopoulos, and M. S. Lionakos. Aberrant type 1 immunity drives mucosal fungal infection susceptibility. *Science*, 371:eaay5731, 2021.

J. R. Dwyer, J. J. Racine, H. D. Chapman, A. Quinlan, M. Presa, G. A. Stafford, I. Schmitz, and D. V. Serreze. Nfkbid overexpression in NOD mice elicits complete type 1 diabetes resistance associated with enhanced thymic deletion of pathogenic CD8 T-cells and increased numbers and activity of regulatory T-cells. *J. Immunol.*, in press.

C. Izquierdo, E. I. Rivas, A. Z. Ortiz, S. Malo, M. Presa, N. Garabatos, C. Mora, F. Rodriguez, D. V. Serreze, J. Verdager, and T. Stratmann. Manipulation of diabetogenic CD4 T cells by targeted peptide delivery via a CTLA4Ig-fusion DNA vaccine. *J. Immunol.*, submitted.

Q. Wang, J. J. Racine, H. D. Chapman, J. R. Dwyer, T. Stearns, P. A. Silveira, and D. V. Serreze. *Ephb2* gene variants regulate the development of autoimmune diabetes participatory B-lymphocytes. *J. Exp. Med.*, in revision.

Book Chapters and Reviews

E. H. Leiter, M. Prochazka, D. L. Coleman, D. V. Serreze, and L. D. Shultz. Genetic factors predisposing to diabetes susceptibility in mice. In: *The Immunology of Diabetes Mellitus*. M.A. Jaworski, G.D. Mollnar, R.V. Rajotte, and B. Singh, eds. Elsevier, Amsterdam, 1986.

E. H. Leiter, D. V. Serreze, and M. Prochazka. The genetics and epidemiology of diabetes in NOD mice. *Immunology Today* 11:147, 1990

E. H. Leiter and D. V. Serreze. Autoimmune diabetes in the Nonobese Diabetic (NOD) mouse: suppression of immune defects by bone marrow transplantation and implications for therapy. *Clin. Immunol. Immunopath.* 59:323, 1991.

E. H. Leiter and D. V. Serreze. Antigen presenting cells and the immunogenetics of autoimmune diabetes in NOD mice. *Regional Immunology*, 4:263, 1992.

D. V. Serreze. Autoimmune diabetes results from genetic defects manifest by antigen presenting cells. *FASEB*, 7:1092, 1993.

D. V. Serreze and E. H. Leiter. Genetic and pathogenic basis of autoimmune diabetes in NOD mice. *Current Opinions in Immunology*, 6:900, 1994.

D. V. Serreze and E. H. Leiter. Insulin dependent diabetes mellitus (IDDM) in NOD mice and BB rats: origins in hematopoietic stem cell defects and implications for therapy. In: *Lessons from Animal Diabetes V*, E. Shafrir, ed. Smith-Gordon, London, 1996, p59.

D. V. Serreze. The identity and ontogenic origins of autoreactive T lymphocytes in NOD mice. In: *NOD mice and related strains: research applications in diabetes, AIDS, cancer, and other diseases*. E. H. Leiter and M. A. Atkinson, eds. Landes Bioscience Publishers, Austin. 1998, p71.

D. V. Serreze. Genetic control of immunological responses. In: *The Encyclopedia of Genetics*. E. C. R. Reeve, ed. Fitzroy Dearborn Publishers, London. 2001.

D. V. Serreze and E. H. Leiter. Genes and pathways underlying autoimmune diabetes in NOD mice. In: *Molecular Pathology of Insulin Dependent Diabetes Mellitus*. M. G. von Herrath, ed. Karger Press, New York. 2001, p31.

D. V. Serreze and P. A. Silveira. The role of B lymphocytes as key antigen presenting cells in the development of T cell mediated autoimmune type 1 diabetes. In: *B cell Biology and Autoimmunity*. D. Nemazee, ed. Karger Press, New York. 2003. p212.

D. V. Serreze and D. C. Roopenian. Was there type 1 diabetes in the Olduvai Gorge? In: *Immunology of type 1 diabetes*. G. Eisenbarth, ed. Landes Bioscience Publishers, Austin. 2003. p323.

T. Pearson, T. G. Markees, D. V. Serreze, M. A. Pierce, L. S. Wicker, L. B. Peterson, L. D. Shultz, J. P. Mordes, A. A. Rossini and D. L. Greiner. Genetic separation of the transplantation tolerance phenotype and the autoimmune phenotype in NOD mice. *Reviews in Endocrine and Metabolic Disorders*, 4:255, 2003.

T. Pearson, T. G. Markees, D. V. Serreze, M. A. Pierce, L. S. Wicker, L. B. Peterson, L. D. Shultz, J. P. Mordes, D. L. Greiner and A. A. Rossini. Islet cell autoimmunity and transplantation tolerance: two distinct mechanisms? *Ann. NY Acad. Sci.* 1005:148, 2003.

J. P. Mordes, D. V. Serreze, D. L. Greiner, and A. A. Rossini. Animal models of autoimmune diabetes mellitus. In: *Diabetes Mellitus: A Fundamental and Clinical Text, 3rd edition*. D. LeRoith, ed. Lippincott, Williams, and Wilkins Publishers, New York. 2004. p591.

T. P. DiLorenzo and D. V. Serreze. The good turned ugly: Immunopathogenic basis for diabetogenic CD8 T cells in NOD mice. *Immunol. Rev.*, 204:250, 2005.

D. V. Serreze and Y-G. Chen. Of mice and men: use of animal models to identify possible interventions for the prevention of autoimmune type 1 diabetes in humans. *Trends in Immunol.* 26:603, 2005.

P. A. Silveira, D. V. Serreze, and S. T. Gray. Invasion of the killer Bs in type 1 diabetes. *Frontiers in Bioscience*, 12:2183, 2007.

D. V. Serreze, M. P. Marron, and T. P. DiLorenzo. "Humanized" HLA transgenic NOD mice to identify pancreatic β cell autoantigens of potential clinical relevance to type 1 diabetes. *Ann. NY Acad. Sci.*, 1103:103, 2007.

D. V. Serreze and P. A. Silveira. To be an autoreactive B (cell) or not to be: are lessons learned about this question in type 1 diabetes applicable to autoimmune thyroiditis? In: *The Thyroid and Autoimmunity*. W. M. Wiersinga, H. A. Drexhage, and A. P. Weetman, eds. Thieme Verlag Publishers, Stuttgart, Germany. 2007. p104-109.

E. H. Leiter, P. Reifsnyder, J. Driver, S. Kamdar, C. Choissy-Rossi, D. V. Serreze, M. Hara, and A. Chervonsky. Unexpected functional consequences of xenogeneic transgene expression in beta cells of NOD mice. *Diabetes, Obesity, and Metabolism*, 2:14, 2007.

J. Wesolowski, V. Alzogaray, J. Reyelt, M. Unger, K. Juarez, M. Urrutia, A. Cauerfff, W. Danquah, B. Rissiek, F. Scheuplein, N. Schwarz, S. Adriouych, O. Boyer, M. Seman, A. Licea, D. V. Serreze, F. A. Goldbaum, F. Haag, and F. Koch-Nolte. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. *Med. Microbiol. Immunol.*, 198:157, 2009.

D. V. Serreze, M. Niens, J. Kulik, and T. P. DiLorenzo. Bridging mice to men: using HLA transgenic mice to enhance the future prediction and prevention of

autoimmune type 1 diabetes in humans. In: *Mouse Models for Drug Discovery*. M. Wiles and G. Proetzel, eds. Humana Press, Totowa, NJ. 2009, p119.

J. P. Driver, D. V. Serreze, and Y-G. Chen. Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. In: *Immunopathology of the Pancreas in Type-1 Diabetes. Seminars in Immunopathology*, 33:67, 2011.

H. Wekerle, A. Flugel, L. Fugger, G. Schett, and D. Serreze. Autoimmunity's next top models. *Nature Medicine*, 18:66, 2012.

A. Komaromy, K. Abrams, J. Heckenlively, S. Lundy, C. McPhee-Leeth, P. MohanKumar, S. Petersen-Jones, D. Serreze, and A. van der Woerd. Sudden acquired retinal degeneration syndrome (SARDS) - a review and proposed strategies towards a better understanding of pathogenesis, early diagnosis, and therapy. *Veterinary Ophthalmology*, 19:319, 2016.